Picture of AptarGroup logo

ATR — AptarGroup News Story

0.000.00%
us flag iconLast trade - 00:00
Basic MaterialsConservativeLarge CapHigh Flyer

Aptar Q3 profit falls on Russia deconsolidation charge

Aptar Q3 profit falls on Russia deconsolidation charge


Overview

  • Drug delivery and dispensing firm's Q3 sales rose 6%, beating analyst expectations

  • Adjusted EPS for Q3 was $1.52, beating analyst expectations

  • Reported EPS fell to $0.51 due to Russian subsidiary deconsolidation


Outlook

  • Aptar sees Q4 2026 adj EPS between $1.39 and $1.47

  • Company expects full-year results supported by Pharma growth, especially in consumer healthcare and injectables

  • Closures segment expected to see increased demand, driven by beverage technology innovation


Result Drivers

  • RUSSIAN DECONSOLIDATION - A government decree drove a $60.4 mln after-tax charge, cutting reported EPS by $0.94

  • PHARMA SEGMENT - Co said growth in central nervous system, pulmonary, injectables and consumer healthcare therapies drove Pharma segment sales

  • BEAUTY DEMAND - Increased demand for prestige fragrance dispensing, color cosmetics and hair care applications boosted Beauty segment sales

  • CLOSURES INNOVATION - Strong demand for beverage dispensing closures, bottled water, concentrates and condiments drove Closures segment growth


Company press release: ID:nBw8Y4wjva


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$1.02 bln

$984.44 mln (7 Analysts)

Q3 Adjusted EPS

Beat

$1.52

$1.47 (8 Analysts)

Q3 EPS

$0.51

Q3 Net Income

$33 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the non-paper containers & packaging peer group is "buy"

  • Wall Street's median 12-month price target for AptarGroup, Inc. is $154.78, about 18.5% above its October 29 closing price of $130.64

  • The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 21 three months ago


Reuters Recommended Reads

  • Oct 29 - US drugmaker Eli Lilly beats Q3 revenue estimates on product demand, lifts FY outlook

  • Oct 29 - Ligand Pharmaceuticals Q3 royalty revenue jumps 51%

  • Oct 29 - Phathom Pharmaceuticals Q3 revenue rises 71%


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on AptarGroup

See all news